Project Details
Description
A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with "Systemic Sclerosis associated Interstitial Lind Disease (SSc-ILD)
| Status | Finished |
|---|---|
| Effective start/end date | 12/14/15 → 6/30/19 |
Funding
- BOEHRINGER-INGELHEIM PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.